NCT04022096View on ClinicalTrials.gov

Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Esophagitis

PHASE3CompletedINTERVENTIONAL
Enrollment

351

Participants

Timeline

Start Date

June 18, 2019

Primary Completion Date

June 23, 2021

Study Completion Date

June 23, 2021

Conditions
Healed Erosive Esophagitis
Interventions
DRUG

Tegoprazan 25mg QD

Tegoprazan 25mg tablets will be orally administered, once daily, for up to 6 months.

DRUG

Lansoprazole 15mg QD

Lansoprazole 15mg capsules will be orally administered, once daily, for up to 6 months.

Trial Locations (1)

133-792

Hanyang University Seoul Hospital, Seoul

Sponsors
All Listed Sponsors
lead

HK inno.N Corporation

INDUSTRY

NCT04022096 - Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Esophagitis | Biotech Hunter | Biotech Hunter